Recent Updates
Recently added Catalysts
COLL

Collegium to Present at the 16th Annual Needham Healthcare Conference

Key Takeaway: CANTON, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 16th Annual Needham Healthcare Conference in New York City. The presentation will take place at 10:40 a.m. ET on Wednesday, April 5, 2017 at

Full Press Release Details

CANTON, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 16th Annual Needham Healthcare Conference in New York City. The presentation will take place at 10:40 a.m. ET on Wednesday, April 5, 2017 at the Westin New York Grand Central Hotel.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact Data

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.
Last updated: Mar 28, 2017